5th mRNA Analytical Development and Quality Control Summit

Memo

As the mRNA field evolves beyond vaccines into diverse modalities, delivery systems, and therapeutic areas, analytical rigor has never been more critical. With the FDA intensifying scrutiny on CMC packages and new draft guidelines emerging from the EMA, USP, NIST, and FDA, the call for harmonized, phase-appropriate analytical and quality control strategies is needed now more than ever. mRNA pipelines are maturing, but complexity continues to grow - from dsRNA impurities and potency assay variability to scaling analytical methods for GMP readiness. As the field faces increasing regulatory expectations and new modalities like circular and self-amplifying RNA enter the clinic, the industry must redefine what analytical excellence looks like. This summit will unite the analytical, quality, and regulatory leaders driving this transformation to build a new standard for mRNA characterization, control, and compliance. URLs:Tickets: https://go.evvnt.com/3320326-2?pid=5569 Brochure: https://go.evvnt.com/3320326-3?pid=5569  Date and Time: Tue, 24 Feb 2026 08:00 - Thu, 26 Feb 2026 18:00 Venue details: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, Massachusetts, 02215, United States Category: Conferences | Health Prices:Drug Developer Pricing Conference + Workshop Day: USD 4197.00,Drug Developer Pricing Conference Only: USD 2999.00,Academic Pricing Conference + Workshop Day: USD 3597.00,Academic Pricing Conference Only: USD 2599.00,Service Provider Pricing Conference + Workshop Day: USD 5197.00,Service Provider Pricing Conference Only: USD 3799.00 Speakers: James Shu - Vice President - Analytical Science AboGen Inc., Yurong Guo - Sr. Director - Arcturus Therapeutics, Bohdan Andreiuk - Senior Scientist - New Modality Preformulation and Lipid Nanoparticle formulation AstraZeneca, Zack Zhang - Director - Analytical Development Beam Therapeutics Inc., Andreas Czech - Director - BioNTech, Atsuko Sakurai-Sangria - Expert Member Best Practices mRNA - Centivax, Stefan Heinz - Director - Analytical Science and Strategy CureVac SE, Faisal Ansari - QC Specialist analyst - Genetech Biotech, Jean-Francois Dierick - Strategic Analytical Validation and Lifecycle Lead - GlaxoSmithKline, Diana Posadas - Director - GreenLight BioSciences, Yun-Ting Kao - Senior Scientist - Immunomic Therapeutics, Inc, Melanie Carroll - Quality Control - Manager Inventprise, Ahmed Al Azzam - Research Analyst Associate - Massachusetts College of Pharmacy and Health Sciences, Charles Kline - Associate Vice President - Regulatory Affairs and Chemistry Manufacturing Controls - Merck and Co, Salette Martinez - Associate Director - Analytical Development nChroma Bio, Amanda Green - Associate Director - Quality Assurance - Orna Therapeutics, Kari Efferen - Senior Director and Head of Analytical Development - Pfizer, Manasa Chillara - Doctoral Researcher - Rensselaer Polytechnic Institute, Samuel Valentin - Quality Control Associate - Takeda Pharmaceutical, Elisabeth Boucher - Associate Director, Analytical Development - Tessera Therapeutics, Benjamin Hall - Senior Scientist - Analytical Development - Tessera Therapeutics, Diane McCarthy - Vice President, Global Biologics U.S. - Pharmacopeia